As global trade realignments and tariff uncertainties reshape pharmaceutical supply chains, India is positioning itself as a resilient and adaptive force. With pharmaceutical exports reaching USD 30.5 billion in FY2025—a 9.3% increase over the previous year—the country is laying the groundwork to double its pharma exports to USD 65 billion by 2030.

In this dynamic environment, Rubix Data Sciences, a leading provider of risk management and compliance monitoring solutions, has released a comprehensive industry report that captures how Indian pharmaceutical companies are navigating volatility by focusing on complex generics, regulatory strength, and global expansion.

The report comes at a critical juncture. The United States, which accounts for over 32% of India’s pharma exports, is reportedly considering imposing tariffs as high as 200% on imported pharmaceuticals. In response, Indian companies are proactively investing in US-facing manufacturing, entering strategic partnerships and acquisitions in the US and Europe, and increasing the share of differentiated and complex generics in their portfolios—particularly those aligned with upcoming patent expirations.

Rubix’s findings indicate a clear strategic pivot in India’s pharma sector. Companies are expanding their reach in advanced therapeutic segments such as oncology, CNS, and anti-diabetics, while also reducing over-dependence on China, which still accounts for 74% of bulk drug imports. The shift towards supplier diversification and regulatory alignment is central to building long-term resilience.

“The rise in exports is a strong indicator of how Indian pharma is adapting to global uncertainties,” said Mohan Ramaswamy, Co-founder and CEO of Rubix Data Sciences. “From tariff risks to regulatory challenges, Indian firms are responding with strategic maturity, and we expect this momentum to accelerate in the coming years.”

As the August 1 tariff deadline looms, Rubix’s industry insights provide timely intelligence for stakeholders across the pharmaceutical ecosystem. In a world of rising protectionism and politicised supply chains, India’s choices today could define global access to affordable medicine tomorrow.

Rubix Data Sciences empowers businesses with data-driven insights to manage credit risk, ensure compliance, and build resilient global supply chains—enabling smarter, risk-aware decisions in a complex world.